Dimensional Fund Advisors LP Purchases 260,288 Shares of Amphastar Pharmaceuticals, Inc. (AMPH)
Dimensional Fund Advisors LP boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 32.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,061,188 shares of the company’s stock after buying an additional 260,288 shares during the period. Dimensional Fund Advisors LP’s holdings in Amphastar Pharmaceuticals were worth $15,388,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Amphastar Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 2,179,764 shares of the company’s stock worth $31,607,000 after buying an additional 8,744 shares in the last quarter. Rothschild Asset Management Inc. bought a new position in Amphastar Pharmaceuticals during the first quarter valued at approximately $9,056,000. Teachers Advisors LLC increased its position in Amphastar Pharmaceuticals by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 542,953 shares of the company’s stock valued at $10,001,000 after buying an additional 1,693 shares during the period. Bank of New York Mellon Corp increased its position in Amphastar Pharmaceuticals by 11.4% in the first quarter. Bank of New York Mellon Corp now owns 519,802 shares of the company’s stock valued at $7,536,000 after buying an additional 53,214 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Amphastar Pharmaceuticals by 1.0% in the first quarter. JPMorgan Chase & Co. now owns 517,900 shares of the company’s stock valued at $7,510,000 after buying an additional 5,127 shares during the period. 43.83% of the stock is currently owned by institutional investors.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) traded down 0.07% during trading on Tuesday, reaching $14.75. The company’s stock had a trading volume of 14,823 shares. Amphastar Pharmaceuticals, Inc. has a one year low of $12.05 and a one year high of $21.75. The firm has a market capitalization of $681.38 million, a P/E ratio of 191.56 and a beta of 1.65. The stock has a 50-day moving average of $17.16 and a 200 day moving average of $15.91.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The business had revenue of $65.20 million during the quarter, compared to analysts’ expectations of $63.40 million. During the same quarter in the prior year, the firm earned $0.23 earnings per share. The business’s revenue was down 4.1% compared to the same quarter last year. On average, equities research analysts predict that Amphastar Pharmaceuticals, Inc. will post $0.40 EPS for the current fiscal year.
Amphastar Pharmaceuticals announced that its board has initiated a share repurchase plan on Wednesday, August 9th that authorizes the company to repurchase $20.00 million in shares. This repurchase authorization authorizes the company to purchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.
Several research analysts have recently commented on AMPH shares. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 16th. Piper Jaffray Companies set a $19.00 price objective on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Wells Fargo & Company reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Saturday, July 22nd. TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Monday, June 26th. Finally, BidaskClub downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.86.
In other news, Director Jason B. Shandell sold 11,482 shares of the company’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $16.92, for a total value of $194,275.44. Following the completion of the sale, the director now directly owns 241,342 shares in the company, valued at $4,083,506.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $17.07, for a total value of $170,700.00. Following the completion of the sale, the director now owns 28,844 shares of the company’s stock, valued at $492,367.08. The disclosure for this sale can be found here. Insiders have sold 36,482 shares of company stock valued at $620,125 in the last three months. Insiders own 11.10% of the company’s stock.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.